BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Questcor Pharmaceuticals, Inc. (Headquarters) (QSC) Investor Lawsuit Over Alleged False and Misleading Statements Announced by Shareholders Foundation


10/2/2012 9:33:37 AM

SAN DIEGO, CA--(Marketwire - October 02, 2012) -

The Shareholders Foundation, Inc. announces that a lawsuit was filed by an investor in Questcor Pharmaceuticals, Inc. (QCOR) shares over alleged securities laws violations by Questcor Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements regarding its injectable drug H.P. Acthar Gel.

Investors who purchased shares of Questcor Pharmaceuticals, Inc. (QCOR) have certain options and should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

The plaintiff alleges that Questcor Pharmaceuticals, Inc. and certain of its officers and directors issued between April 26, 2011 and September 21, 2012 allegedly false and misleading statements about the effectiveness of Acthar as a treatment for multiple sclerosis and nephrotic syndrome, making it allegedly impossible for shareholders to gain a meaningful or realistic understanding of the drug's prospects and market success.

On September 24, 2012, Questcor Pharmaceuticals, Inc. disclosed in a filing with the SEC that on September 21, 2012, Questcor Pharmaceuticals, Inc. became aware of a U.S. government investigation involving Questcor Pharmaceuticals' promotional practices.

Earlier Aetna Inc. said it would limit coverage of Questcor's top-selling drug, H.P. Acthar. Aetna issued a Clinical Policy Bulletin stating that based on review of medical studies Acthar was "not medically necessary" for certain conditions for which it has been prescribed and as a result Aetna would limit the coverage of H.P. Acthar.

Shares of Questcor Pharmaceuticals, Inc. dropped from as high as $50.52 on September 18, 2012 to as low as $17.75 per share on September 27, 2012.

Those who purchased shares of Questcor Pharmaceuticals, Inc., have certain options and should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.


CONTACT:
Shareholders Foundation, Inc.
Trevor Allen
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->